+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer



Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer



Seminars in Oncology 16(4 Suppl 6): 83-97



A new concept in the natural history of gastrointestinal (GI) cancer suggests that recurrence of this malignancy can be separated into two types. Hematogenous and lymphatic metastases occur before surgical removal of the primary cancer. The spread of cancer to the resection site and to peritoneal surfaces occurs at the time of surgical removal of the primary tumor. Surgical trauma leads to a dispersal of malignant tumor emboli, which then implant within the raw tissue surfaces of the resection site and abraded peritoneal surfaces. Instillation of chemotherapy directly into the peritoneal cavity, as part of GI surgery, provides cytotoxic levels of drug that may change the natural history of GI cancer. The most common sites of disease recurrence have been, in the past, at the resection site and on peritoneal surfaces. With the optimal use of intraperitoneal chemotherapy, these sites of surgical treatment failure should no longer occur. Early phase I and II and pharmacologic studies suggest that an effective dose and schedule have been achieved, that toxicity is at reasonable levels, and that responses with small volumes of intra-abdominal cancer are exceptionally high. Chemotherapy that has an impact on the surgical event by decreasing cancer spread to the resection site and to peritoneal surfaces may significantly improve survival and quality of life in patients with GI cancer.

(PDF emailed within 1 workday: $29.90)

Accession: 033093807

Download citation: RISBibTeXText

PMID: 2669141


Related references

Gastrointestinal malignancy: rationale for adjuvant therapy using early postoperative intraperitoneal chemotherapy. British Journal of Surgery 76(10): 1082-1090, 1989

The rationale for early postoperative intraperitoneal chemotherapy for gastric cancer. Cancer Treatment and Research 55: 143-159, 1991

Hyperthermic intraperitoneal chemotherapy plus high-frequency diathermic therapy followed by intravenous chemotherapy versus intravenous chemotherapy alone for postoperative adjuvant treatment of gastrointestinal cancer: a comparative research study. Journal of BUON 21(6): 1510-1517, 2017

Early postoperative intraperitoneal chemotherapy as an adjuvant therapy to surgery for peritoneal carcinomatosis from gastrointestinal cancer: pharmacological studies. Cancer Research 50(18): 5790-5794, 1990

Intraperitoneal gemcitabine chemotherapy treatment for patients with resected pancreatic cancer: rationale and report of early data. International Journal of Surgical Oncology 2011: 161862-161862, 2012

Early postoperative intraperitoneal chemotherapy for the treatment of advanced gastric cancer. Medicina 47(1): 63-69, 2011

Early postoperative intraperitoneal chemotherapy as adjuvant treatment of colorectal cancer, experimental study. Gastroenterology 108(4 SUPPL ): A460, 1995

Hyperthermic intraperitoneal chemotherapy + early postoperative intraperitoneal chemotherapy versus hyperthermic intraperitoneal chemotherapy alone: assessment of survival outcomes for colorectal and high-grade appendiceal peritoneal carcinomatosis. American Journal of Surgery 210(3): 424-430, 2015

Intraperitoneal free cancer cells in gastric cancer: pathology of peritoneal carcinomatosis and rationale for intraperitoneal chemotherapy/hyperthermic intraperitoneal chemotherapy in gastric cancer. Translational Gastroenterology and Hepatology 1: 69, 2017

Rationale for early postoperative intraperitoneal chemotherapy to eradicate tumor cells disseminated at the time of resection of intraabdominal adenocarcinoma. Journal of Cancer Research & Clinical Oncology 116(SUPPL PART 1): 685, 1990

Intraoperative and early postoperative intraperitoneal chemotherapy--adjuvant treatment for locally advanced digestive system cancer. Revista Medico-Chirurgicala a Societatii de Medici Si Naturalisti Din Iasi 108(2): 403-408, 2005

Efficacy of Early Postoperative Intraperitoneal Chemotherapy After Complete Surgical Resection of Peritoneal Metastasis from Colorectal Cancer: A Case-Control Study from a Single Center. Annals of Surgical Oncology 23(7): 2266-2273, 2018

Rationale for the intraperitoneal approach to surgical adjuvant chemotherapy of gastric cancer. Cancer Treatment and Research 55: 41-50, 1991

Early Postoperative Chemotherapy After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Isolated Peritoneal Carcinomatosis of Colon Cancer: A Multicenter Study. Annals of Surgical Oncology 23(3): 863-869, 2016

Early postoperative intraperitoneal chemotherapy for gastric cancer. Cancer Treatment and Research 55: 265-275, 1991